Sectors & Industries HealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2025)
Top general drug manufacturer stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...

Overview Zen Rating Price Value Growth Financials Momentum Sentiment Forecast

General Drug Manufacturers is Zen Rated A and is the 4th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Price	Price Target	Upside/Downside	Consensus	Analysts	Fore. Revenue Growth	Fore. Earnings Growth	Forecast ROE	Forecast ROA
GRFS	GRIFOLS SA	$6.91B	$10.05	$10.30	2.49%	Hold	1	8.48%	125.53%	17.25%	4.74%
GILD	GILEAD SCIENCES INC	$135.34B	$108.80	$118.00	8.46%	Strong Buy	13	3.08%	23.84%	63.15%	21.44%
NVS	NOVARTIS AG	$221.70B	$114.52	N/A	N/A	N/A	N/A	0.84%	12.57%	45.00%	18.10%
GSK	GSK PLC	$74.54B	$36.47	N/A	N/A	N/A	N/A	2.91%	34.82%	116.09%	27.07%
JNJ	JOHNSON & JOHNSON	$392.14B	$162.98	$169.55	4.03%	Buy	11	3.34%	9.58%	38.66%	15.59%
AMGN	AMGEN INC	$160.37B	$298.25	$310.91	4.24%	Hold	11	2.55%	26.18%	195.12%	13.55%
AZN	ASTRAZENECA PLC	$214.71B	$69.26	N/A	N/A	N/A	N/A	-1.62%	31.84%	22.17%	8.56%
BMY	BRISTOL MYERS SQUIBB CO	$97.81B	$48.06	$56.00	16.52%	Hold	9	-4.26%	29.38%	64.87%	12.20%
ABBV	ABBVIE INC	$338.09B	$191.40	$216.00	12.85%	Buy	12	6.76%	88.30%	2,106.80%	21.97%
PFE	PFIZER INC	$139.75B	$24.58	$27.33	11.20%	Hold	6	-0.31%	31.04%	17.43%	7.57%
LLY	ELI LILLY & CO	$721.70B	$761.50	$1.00k	31.58%	Strong Buy	9	19.83%	46.70%	280.74%	49.51%
SCLX	SCILEX HOLDING CO	$64.30M	$9.25	$630.00	6,710.81%	Strong Buy	1	17.29%	N/A	N/A	-194.10%
BIIB	BIOGEN INC	$18.86B	$128.69	$172.88	34.33%	Buy	16	-2.24%	15.50%	14.12%	8.55%
MRK	MERCK & CO INC	$204.70B	$81.52	$99.29	21.79%	Buy	7	4.40%	15.63%	59.66%	25.05%
SNY	SANOFI	$122.90B	$48.65	$65.00	33.61%	Hold	1	8.05%	31.14%	9.04%	5.28%
OGN	ORGANON & CO	$2.51B	$9.64	$17.33	79.80%	Strong Buy	3	-0.17%	15.18%	200.48%	8.26%
AMRN	AMARIN CORP PLC	$326.96M	$15.79	$12.00	-24.00%	Strong Sell	1	-1.38%	N/A	-19.23%	-13.90%
MIRA	MIRA PHARMACEUTICALS INC	$34.18M	$2.02	N/A	N/A	N/A	N/A	N/A	N/A	-536.02%	-495.38%

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Jul 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Grifols Sa (NASDAQ:GRFS)

Grifols Sa (NASDAQ:GRFS) is the #1 top general drug manufacturer stock out of 18 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Grifols Sa (NASDAQ:GRFS) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: B, Financials: C, and AI: B.

Grifols Sa (NASDAQ:GRFS) has a Due Diligence Score of 29, which is -15 points lower than the general drug manufacturer industry average of 44. Although this number is below the industry average, our proven quant model rates GRFS as a "A".

GRFS passed 12 out of 38 due diligence checks and has average fundamentals. Grifols Sa has seen its stock return 24.69% over the past year, overperforming other general drug manufacturer stocks by 39 percentage points.

Grifols Sa has an average 1 year price target of $10.30, an upside of 2.49% from Grifols Sa's current stock price of $10.05.

Grifols Sa stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Grifols Sa, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) is the #2 top general drug manufacturer stock out of 18 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Gilead Sciences (NASDAQ:GILD) is: Value: B, Growth: C, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: B.

Gilead Sciences (NASDAQ:GILD) has a Due Diligence Score of 59, which is 15 points higher than the general drug manufacturer industry average of 44.

GILD passed 21 out of 38 due diligence checks and has strong fundamentals. Gilead Sciences has seen its stock return 48.43% over the past year, overperforming other general drug manufacturer stocks by 63 percentage points.

Gilead Sciences has an average 1 year price target of $118.00, an upside of 8.46% from Gilead Sciences's current stock price of $108.80.

Gilead Sciences stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Gilead Sciences, 53.85% have issued a Strong Buy rating, 23.08% have issued a Buy, 23.08% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Novartis Ag (NYSE:NVS)

Novartis Ag (NYSE:NVS) is the #3 top general drug manufacturer stock out of 18 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Novartis Ag (NYSE:NVS) is: Value: C, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: C, and AI: B.

Novartis Ag (NYSE:NVS) has a Due Diligence Score of 39, which is -5 points lower than the general drug manufacturer industry average of 44. Although this number is below the industry average, our proven quant model rates NVS as a "B".

NVS passed 14 out of 38 due diligence checks and has average fundamentals. Novartis Ag has seen its stock return 2.43% over the past year, overperforming other general drug manufacturer stocks by 17 percentage points.

What are the general drug manufacturer stocks with highest dividends?

Out of 13 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) has an annual dividend yield of 6.02%, which is 3 percentage points higher than the general drug manufacturer industry average of 3.34%.

Organon & Co's dividend payout ratio of 38.5% indicates that its high dividend yield is sustainable for the long-term.

2. Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) has an annual dividend yield of 5.17%, which is 2 percentage points higher than the general drug manufacturer industry average of 3.34%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 121.6% indicates that its high dividend yield might not be sustainable for the long-term.

3. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.55%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.34%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 88.1% indicates that its high dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks down?

General drug manufacturer stocks were down -1.62% in the last day, and down -2.74% over the last week. Gsk was the among the top losers in the drug manufacturers - general industry, dropping -4.73% yesterday.

GSK is trading lower after an FDA advisory panel reportedly voted against its blood cancer drug Blenrep in combination with bortezomib and dexamethasone for previously treated patients.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Organon & Co has a valuation score of 71, which is 27 points higher than the general drug manufacturer industry average of 44. It passed 5 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -54.44% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -40 percentage points.

2. Merck & Co (NYSE:MRK)

Merck & Co (NYSE:MRK) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Merck & Co has a valuation score of 57, which is 13 points higher than the general drug manufacturer industry average of 44. It passed 4 out of 7 valuation due diligence checks.

Merck & Co's stock has dropped -35.25% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -21 percentage points.

3. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 86, which is 42 points higher than the general drug manufacturer industry average of 44. It passed 6 out of 7 valuation due diligence checks.

Biogen's stock has dropped -43.64% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -30 percentage points.

Are general drug manufacturer stocks a good buy now?

35.71% of general drug manufacturer stocks rated by analysts are a hold right now. On average, analysts expect general drug manufacturer stocks to rise by 53.05% over the next year.

5.56% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 44.44% of general drug manufacturer stocks are rated B (Buy), 44.44% are rated C (Hold), 5.56% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 37.55x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

General Drug Manufacturer Stocks FAQ

1. Grifols Sa (NASDAQ:GRFS)

2. Gilead Sciences (NASDAQ:GILD)

3. Novartis Ag (NYSE:NVS)

1. Organon & Co (NYSE:OGN)

2. Pfizer (NYSE:PFE)

3. Sanofi (NASDAQ:SNY)

1. Organon & Co (NYSE:OGN)

2. Merck & Co (NYSE:MRK)

3. Biogen (NASDAQ:BIIB)

Company

Stock Tools

Stock Ideas